[ad_1]
New York, June 9, 2021 (Global News Agency)-Reportlinker.com announced the release of the report “2021 Bispecific MAbS Global Market Report: COVID 19 Growth and Changes to 2030”- https://www.reportlinker.com/p06090630/?utm_source=GNW
Mylan NV, Daiichi Sankyo Corporation, Abbott and AstraZeneca.
The global bispecific MAbS market is expected to grow from USD 2.93 billion in 2020 to USD 3.75 billion in 2021, with a compound annual growth rate (CAGR) of 28%. The growth is mainly due to the company’s resumption of operations and adapting to the new normal, while recovering from the effects of COVID-19, which earlier led to restrictive containment measures including social distancing, remote work and closure of business activities, leading to operations challenge. It is estimated that by 2025, the market will reach a compound annual growth rate of 28% to reach US$10 billion.
The bispecific monoclonal antibody or bispecific monoclonal antibody market includes the sales of bispecific monoclonal antibodies and related services. Bispecific monoclonal antibody is an artificial protein that can combine two or more antigens into a single product.
Bispecific monoclonal antibodies are used to improve the immune response under various medical conditions, and are used in the fields of drug delivery and cancer immunotherapy.
The bispecific MAb market covered by this report is subdivided into catumaxomab (removab); Bonatumumab; Duligomab; SAR 156597. It is also subdivided into in vivo according to product type; in vitro, entering cancer through indications; autoimmune diseases; inflammatory diseases; infectious diseases; microbial diseases; others and eventually used in hospitals; research institutions; others.
The availability of various cancer alternative treatments is expected to limit the growth of the bispecific monoclonal antibody market. Alternative cancer treatment methods and methods for the treatment of cancer, including diet therapy, acupuncture, homeopathy and herbal therapy, have become more and more popular in recent years due to the side effects of chemotherapy and anticancer agents.
For example, Ayurvedic medicine is an ancient Indian medical system that uses a series of techniques and treatment methods to treat cancer. Many herbs used in Ayurveda have anti-cancer properties, such as Andrographis paniculata.
According to the World Health Organization (WHO), some countries are still responding to plant-based treatments as their main source of medicine, while developing countries are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the sales of biological products and thus the bispecific MAbS market.
In addition, the global homeopathic product market was valued at US$5.6 billion in 2018 and is expected to reach US$18.6 billion by the end of 2027, growing at a compound annual growth rate of 14% during the forecast period. Cheaper alternative drugs increase competition in the biologics market, thereby hindering the growth of the bispecific MAb market in the near future.
Companies in the bispecific MAbS market are increasingly investing in various strategic initiatives, such as collaborations and partnerships, to expand the company’s product portfolio and geographic presence. For example, in June 2020, the US-based biopharmaceutical company AbbVie Inc. and the Danish biotechnology company Genmab A/S signed a cooperation agreement to develop and commercialize antibody therapies for cancer treatment. The two companies will jointly study Genmab A/S’s three early bispecific antibody drug candidates, including DuoHexaBody-CD37, epcoritamab and DuoBody-CD3x5T4, while exploring new antibody therapies. In addition, in July 2020, Atreca, Inc., a clinical-stage biotechnology company headquartered in the United States, established a strategic partnership with Xencor, Inc. to develop, discover and commercialize new T cell-binding bispecific antibodies as tumor treatments. Potential therapies. Xencor, Inc. is a US-based biopharmaceutical company dedicated to the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
In September 2018, Tokyo-based pharmaceutical company Otsuka Pharmaceutical completed the acquisition of Visterra Inc. and its antibody engineering platform for US$430 million. The acquisition is expected to help Otsuka Pharmaceutical Co., Ltd. establish proprietary drug development and discovery work through corporate projects including nephrology and other diseases. Visterra, Inc. is a US-based biotechnology company dedicated to the development of antibody-based therapies for kidney and other difficult-to-treat diseases. The Hierotope platform of Visterra Inc. aims to develop antibody-based therapies to modulate and bind targets. The company’s platform includes engineering design of bispecific antibodies and antibody-drug conjugates.
It is expected that during the forecast period, the increasing prevalence of cancer and other chronic diseases will promote the growth of the bispecific monoclonal antibody market. Bispecific monoclonal antibodies have been developed to treat various cancers, infectious diseases, central nervous system diseases and autoimmune diseases.
Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAb) because they target two or more tumor antigens on cells to disrupt cancer progression. According to the World Health Organization, cancer is the second leading cause of death in the world, with an estimated 9.8 million deaths from cancer in 2018. In addition, according to data from the Centers for Disease Control and Prevention, chronic diseases are one of the most common diseases, 6 in the United States, at least 1 in every 10 adults suffers from a chronic disease. Therefore, it is expected that more and more chronic diseases including cancer will drive the demand for the bispecific MAb market to effectively treat these diseases.
Read the full report: https://www.reportlinker.com/p06090630/?utm_source=GNW
on Report linker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need-in one place instantly.
__________________________
Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
[ad_2]
Source link
